Harriet Teare is a research leader focusing on science and emerging technologies at RAND Europe, with a specific interest in emerging technologies in health. Her multidisciplinary training—spanning lab-based research, science policy, and empirical (ethical, legal and governance focused) research—contributes a valuable perspective to help shape the future of healthcare. She has direct experience working across different disciplines and with industry, public and not-for-profit partners, and understands the different motivations and expectations of stakeholders will be crucial in developing a health system that is fit for purpose.
As the deputy director for the Centre for Health, Law and Emerging Technologies at the University of Oxford, Teare developed a research programme in healthcare and policy to tackle crucial questions relating to access to medicines, the changing roles and responsibilities of patients in research and clinical care and the implementation of digital health and genomics. She participated in a number of large-scale European partnerships, including working closely with EFPIA partners Sanofi-Aventis, Eli Lilly, Novo Nordisk, Servier, and Boehringer Ingelheim in an Innovative Medicines Initiative-funded project to consider stratification of type-2 diabetes patients.
As a senior policy advisor at Cancer Research UK, Teare worked alongside the ABPI and BIA to consider implications of UK-wide policy for science and research infrastructure, including relating to the life sciences strategy and immigration policy.
Teare obtained a D.Phil. in organic and medicinal chemistry from Merton College, University of Oxford, developing radiotracers for medical imaging in collaboration with GE Healthcare, and funded by the BBSRC.